FDAsafety guidance66% confidence
Centaur Pharmaceuticals Private Ltd. - 651080 - 12/03/2025
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Sciegen Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Diabetes · SGLT2 Inhibitor
- Sub-indication
- General
Related signal: FDA Submission Overview for Dapagliflozin by Sciegen Pharmaceuticals